Cancer is treated with multiple modalities simultaneously, such as surgery, chemotherapy, and radiation therapy.

Atezolizumab (Tecentriq) plus chemotherapy after surgery did not improve survival in high-risk triple-negative breast cancer, according to a global phase 3 trial.

"What is a tumor?" This is the fundamental question to answer if we want to treat cancer effectively. Our vision of cancer ...

Discussions also delved into the complexities of value-based oncology care, the growing role of real-world data, and strategies to improve access to care in hematology. Across all sessions, a common ...

AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has been approved in the US for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, ...

particularly with respect to lung toxicity. In a phase I/II trial evaluating gavocabtagene autoleucel, a T-cell receptor (TCR) fusion construct targeting MSLN, patients with MSLN-expressing solid ...

Molecular oncology is revolutionizing cancer care by using genetic profiling to tailor personalized treatments, improving ...

Cancer is now the second leading cause of death worldwide, and rates are climbing-especially in younger adults. Breast, ...

The market is responding to this breakthrough. Analysts at Exactitude Consultancy predict that the global immunotherapy ...

1Department of Medical Oncology, West German Cancer Center, University Hospital Essen, Essen, Germany. 2Medical Faculty, University Duisburg-Essen, Essen, Germany. 3National Center of Tumor Diseases ...

Active specific immunotherapy; BCG: Bacille Calmette–Guérin; KLH: Keyhole limpet hemocyanin; MPL: Monophosphoryl lipid A; NSCLC: Non-small-cell lung cancer. Various adjuvant products are ...